Gynecology and Physiopathology of Human Reproduction, University of Bologna and S. Orsola-Malpighi Hospital, Italy.
Center for Applied Biomedical Research (CRBA), Department of Medical and Surgical Sciences, University of Bologna and S. Orsola - Malpighi Hospital, Italy.
Maturitas. 2021 Jan;143:89-95. doi: 10.1016/j.maturitas.2020.09.011. Epub 2020 Oct 2.
The objective of this study was to present an updated picture of the knowledge and attitudes of Italian gynecologists with regard to the genitourinary syndrome of menopause (GSM).
An anonymous survey was sent via electronic mail to 3892 gynecologists. The survey consisted of 32 multiple-choice questions divided into four different areas: 1. general demographics of the respondents; 2. knowledge of GSM; 3. most frequently prescribed therapies; and 4. perception of patient compliance and satisfaction with current therapeutic options.
Knowledge of vulvo-vaginal atrophy (VVA) and attitudes of the gynecologists to its management.
Three hundred and seventy-four out of 3892 invited Italian gynecologists replied to the survey (response rate 9.7 %). Most (84 %) had a good knowledge of GSM and 74 % reported that they investigated it during clinic visits, but most of them underestimated its prevalence. The most frequently prescribed treatment was topical hormonal therapy (60 %), followed by vaginal moisturizers and lubricants (16 %), ospemifene (12 %) and systemic hormone therapy (12 %). According to the clinical experience of respondents, the most effective therapy is local hormonal therapy (36 %), followed by ospemifene (30 %). According to respondents, less than 50 % of patients continue therapy after 12 months, due to the discomfort in vaginal application, the cost of oral therapies and the fear of possible side-effects.
With the limitation of the low response rate, this study suggests that although Italian gynecologists who answered the survey had some knowledge of GSM, they underestimated its prevalence, did not know its most bothersome symptoms and had inadequate knowledge of the efficacy of treatments, patient compliance and satisfaction.
本研究旨在呈现意大利妇科医生对女性泌尿生殖系统绝经综合征（GSM）相关知识和态度的最新情况。
通过电子邮件向 3892 名妇科医生发送了匿名调查。该调查由 32 个多项选择题组成，分为四个不同的领域：1. 受访者的一般人口统计学信息；2. 对 GSM 的了解；3. 最常开的治疗药物；4. 对患者遵医嘱情况和对现有治疗方案满意度的看法。
对阴道萎缩（VVA）的了解程度以及妇科医生对其管理的态度。
在 3892 名受邀的意大利妇科医生中，有 374 名（回应率 9.7%）回复了调查。大多数医生（84%）对 GSM 有较好的了解，并表示他们会在就诊时进行检查，但大多数人低估了其流行程度。最常开的治疗药物是局部激素治疗（60%），其次是阴道保湿剂和润滑剂（16%）、奥昔孕肽（12%）和全身激素治疗（12%）。根据受访者的临床经验，最有效的治疗方法是局部激素治疗（36%），其次是奥昔孕肽（30%）。根据受访者的说法，由于阴道用药的不适、口服治疗的费用以及对可能出现副作用的担忧，不到 50%的患者会在 12 个月后继续治疗。
由于低回应率的限制，本研究表明，尽管参与调查的意大利妇科医生对 GSM 有一定的了解，但他们低估了其流行程度，不了解其最令人困扰的症状，对治疗效果、患者遵医嘱情况和满意度的了解也不够充分。
